| Literature DB >> 32098237 |
Susanne Zoels1, Simon Reiter1, Mathias Ritzmann1, Christine Weiß1, Jasmin Numberger1, Aneka Schütz2, Peter Lindner3, Volker Stefanski4, Ulrike Weiler4.
Abstract
Castration of male pigs without anesthesia is a significant welfare issue. Improvac®, a GnRH vaccine induces an endogenous immune response leading to a decrease in testicular steroids. Consequences of different vaccination schemes on testicular function and carcass quality were evaluated in immunocastrated boars (IC), surgical castrates (SC), and entire males (EM). Therefore, 128 male piglets were assigned to five treatment-groups and a long term follow-up group. IC groups received two vaccinations (V1, V2) with Improvac® at 8 and 12, 12 and 16, or 12 and 18 weeks. Testosterone-concentrations decreased significantly two weeks after V2 in feces and dropped in serum from V2 to slaughter (S) except IC-8/12 without differing significantly. GnRH-binding results indicated the highest values for IC-12/18 animals. While IC-12/16 and IC-12/18 animals showed boar taint compounds below the threshold levels, two IC-8/12 animals had concentrations above the threshold level. Feed-efficiency was higher in EM than in SC with IC in between. In IC compared to EM, a decreasing amount of polyunsaturated-fatty-acids was obvious and GnRH-vaccination reduced penile injuries. The examined vaccination protocols reduce penile injuries, improve feed efficiency and carcass quality, and reliably prevents boar taint, if manufacturer's recommendations concerning vaccination schedules are applied. Therefore immunocastration offers a reliable, animal friendly alternative to surgical castration.Entities:
Keywords: GnRH antibody; androstenone; boar taint; carcass quality; gonadotropin releasing hormones; immunocastration; penile injury; pigs; skatole; testosterone
Year: 2020 PMID: 32098237 PMCID: PMC7070702 DOI: 10.3390/ani10020346
Source DB: PubMed Journal: Animals (Basel) ISSN: 2076-2615 Impact factor: 2.752
Treatment groups, age and weight (kg; mean± SD) at vaccination (V1, V2) and age at slaughter (wk).
| Group |
| Age (wk) at Vaccination | Weight (kg; Mean ± SD) at Vaccination | Number of Animals Slaughtered at an Age of | ||||
|---|---|---|---|---|---|---|---|---|
| V1 | V2 | V1 | V2 | 24 wk | 26 wk | 39 wk | ||
| SC | 24 | -- | -- | -- | -- | 4 | 19 | -- |
| EM | 24 | -- | -- | -- | -- | 6 | 18 | -- |
| IC-8/12 | 24 | 8 | 12 | 17.2 ± 2.1 | 31.3 ± 4.2 | 5 | 19 | -- |
| IC-12/16 | 24 | 12 | 16 | 31.9 ± 2.8 | 53.9 ± 5.0 | 3 | 21 | -- |
| IC-12/18 | 24 | 12 | 18 | 30.4 ± 3.2 | 65.3 ± 6.8 | 5 | 19 | -- |
| IC-12/18X | 8 | 12 | 18 | nd | nd | -- | -- | 7 |
nd: not determined, wk: age in weeks, V1: first vaccination, V2: second vaccination.
Fecal testosterone concentration (ng/mL) (mean ± SD) within groups SC, EM IC-8/12, IC-12/16, and IC-12/18 from 12th to 22nd week of age.
| Groups |
| Weeks of Age | |||||
|---|---|---|---|---|---|---|---|
| 12th | 14th | 16th | 18th | 20th | 22nd | ||
| SC | 5 | 11.0 ± 1.6 a | 12.2 ± 2.9 ac | 10.2 ± 1.3 a | 10.5 ± 1.7 a | 11.6 ± 1.9 a | 10.8 ± 1.5 a |
| EM | 5 | 20.2 ± 17.6 | 26.2 ± 5.2 b | 34.7 ± 8.4 b | 31.5 ± 6.1 b | 34.4 ± 5.3 b | 37.2 ± 17.3 b |
| IC-8/12 | 5 | 15.0 ± 2.6 | 8.3 ± 1.4 a | 10.6 ± 1.7 ac | 9.1 ± 2.4 a | 8.6 ± 2.0 a | 9.3 ± 1.8 a |
| IC-12/16 | 5 | 20.3 ± 3.0 b | 20.0 ± 7.6 cb | 27.3 ± 9.3 d | 12.3 ± 2.4 a | 8.1 ± 1.3 a | 7.6 ± 2.0 a |
| IC-12/18 | 6 | 18.3 ± 5.8 | 19.2 ± 4.2 c | 21.7 ± 6.5 ad | 31.9 ± 8.9 b | 10.1 ± 2.4 a | 10.4 ± 2.3 a |
Differing superscripts within a column indicate significant (p < 0.05) differences between groups. Surgical castrates (SC); entire males (EM); immunocastrated boars in 8th and 12th wk (week of live) (IC8/12); 12th and 16th wk (IC12/16); 12th and 18th wk (IC12/18).
Figure 1Individual (-) and mean (- -) fecal testosterone concentrations (ng/g) of animals in the long term follow-up group IC-12/18X (n = 7) from 12th to 38th week of age; * indicate significant (p < 0.05) differences compared to two weeks earlier; ** indicate significant difference to testosterone concentration compared to week 30.
Testosterone concentration (ng/mL) and absolute GnRH binding (%) (mean ± SD) in serum at second vaccination (V2) and slaughter (S) within the different groups (SC, EM, IC-8/12, IC-12/16, IC-12/18, IC-12/18X).
| Group | Second Vaccination | Slaughter | ||||
|---|---|---|---|---|---|---|
|
| Testosterone | Absolute GnRH Binding (%) |
| Testosterone | Absolute GnRH Binding (%) | |
| SC | - | nd | nd | 23 | 0.06 ± 0.17 a | 4.85 ± 0.24 a |
| EM | - | nd | nd | 24 | 6.63 ± 3.94 b | 4.88 ± 0.44 a |
| IC-8/12 | 5 | 0.90 ± 0.62 | 16.79 ± 7.00 | 24 | 2.88 ± 4.26 a | 30.24 ± 10.13 b |
| IC-12/16 | 5 | 3.22 ± 1.56 a | 20.31 ± 8.91 | 24 | 0.71 ± 1.34 b | 39.58 ± 7.58 c |
| IC-12/18 | 6 | 2.42 ± 1.33 a | 24.58 ± 3.36 | 24 | 0.35 ± 1.27 ab | 44.20 ± 6.12 c |
| IC-12/18X | 7 | 5.21 ± 3.57 | 17.51 ± 9.09 | 7 | 11.98 ± 8.66 c | 41.55 ± 9.41 c |
Differing superscripts within a column or a row indicate significant (p < 0.05) differences between groups. Surgical castrates (SC); entire males (EM); immunocastrated boars in 8th and 12th wk (week of live) (IC8/12); 12th and 16th wk (IC12/16); 12th and 18th wk (IC12/18) and long term follow-up group (IC-12/18X); nd: not determined.
Figure 2Testosterone levels (ng/mL) and absolute GnRH binding (%) in serum of animals slaughtered at batch 1 (∆), batch 2 (o), and batch 3 (□).
Hot carcass weight (HCW, kg), average daily weight gain (ADW; g/d), feed conversion rate (FCR, kg feed/kg gain), intramuscular fat (IMF; %), and fatty acid composition of back fat (SFA, MUFA, PUFA; %) (mean ± SD) of group SC, EM, IC8/12, IC12/16, IC12/18, and IC12/18X.
| Group | SC | EM | IC-8/12 | IC-12/16 | IC-12/18 | |
|---|---|---|---|---|---|---|
| Performance parameters | ||||||
| HCW (kg) | 94.4 ± 6.3 | 97.7 ± 4.9 | 97.4 ± 7.4 | 98.5 ± 6.4 | 98,3 ± 7.6 | n.s. |
| ADW (g/d) | 982.5 ± 69.1 | 1002.1 ± 83.6 | 1001.9 ± 73.9 | 989.2 ± 54.1 | 1028.8 ± 98.1 | n.s. |
| FCR (kg/kg) | 2.3 ± 0.1 a | 2.0 ± 0.1 b | 2.7 ± 0.4 c | 2.2 ± 0.1 a | 2.1 ± 0.1 ab | <0.001 |
| Fat quality | ||||||
| IMF (%) | 1.54 ± 0.33 a | 1.07 ± 0.29 b | 1.46 ± 0.31 a | 1.35 ± 0.46 ab | 1.53 ± 0.46 a | <0.001 |
| SFA (%) | 39.0 ± 1.7 ab | 37.9 ± 1.6 b | 39.9 ± 1.9 ca | 41.7 ± 2.5 d | 41.8 ± 2.1 d | <0.001 |
| MUFA (%) | 44.4 ± 1.7 a | 41.8 ± 2.3 b | 43.7 ± 1.6 ac | 43.2 ± 1.4 ac | 42.8 ± 1.2 bc | <0.001 |
| PUFA (%) | 16.6 ± 1.7 a | 20.4 ± 2.6 b | 16.4 ± 2.0 a | 15.2 ± 2.6 a | 15.5 ± 1.7 a | <0.001 |
| IV | 69.0 ± 2.6 a | 73.4 ± 3.2 b | 68.1 ± 3.1 ac | 65.4 ± 4.4 c | 65.5 ± 3.2 c | <0.001 |
Values with differing subscripts within a line differ significantly (p < 0.05). nd: not determined; IMF: % Intramuscular fat; SFA: % Saturated fatty acids of all fatty acids (100%); MUFA: % Monounsaturated fatty acids of all fatty acids (100%); PUFA: % Polyunsaturated fatty acids of all fatty acids (100%); IV: iodine value; surgical castrates (SC); entire males (EM); immunocastrated boars in 8th and 12th wk (week of live) (IC8/12); 12th and 16th wk (IC12/16); 12th and 18th wk (IC12/18).
Figure 3Androstenone (ng/g) and skatole (ng/g) levels of animals slaughtered at batch 1 (∆), batch 2 (o), and batch 3 (□) with threshold levels for androstenone (1000 ng/g) and skatole (250 ng/g) of group EM, IC-8/12, IC-12/16, IC-12/18, and IC-12/18X.
Number of scars and fresh wounds per animal (mean ± SD) and percentage of animals with lesions and severe injuries (%) of group EM, IC-8/12, IC-12/16, IC-12/18, IC-12/18X.
| Group |
| Scars/Animal | Wounds/Animal | Animals with Lesions (%) | Animals with Severe Injuries (%) |
|---|---|---|---|---|---|
| EM | 24 | 7.92 ± 4.75a | 1.63 ± 1.69a | 91.67a | 12.5a |
| IC-8/12 | 24 | 0.17 ± 0.64b | 0.08 ± 0.28b | 16.67b | 0.00a |
| IC-12/16 | 24 | 0.54 ± 0.93cb | 0.00 ± 0.00cb | 29.17bc | 0.00a |
| IC-12/18 | 24 | 0.83 ± 1.17dc | 0.08 ± 0.41b | 41.67bc | 4.17a |
| IC-12/18X | 7 | 3.29 ± 3.15ad | 0.71 ± 1.25a | 71.43bc | 0.00a |
Values with differing superscripts within a column differ significantly (p < 0.05); entire males (EM); immunocastrated boars in 8th and 12th wk (week of live) (IC8/12); 12th and 16th wk (IC12/16); 12th and 18th wk (IC12/18) and long term follow-up group (IC-12/18X).
Size (cm) of accessory glands and testes and weight (g) of testes (mean ± SD) of group EM, IC-8/12, IC-12/16, IC-12/18, IC-12/18X, and correlation between sizes and testosterone concentration in serum and androstenone concentration in fat tissue at slaughter of IC groups.
| Parameter | Group ( | r Spearman Rho ( | |||||||
|---|---|---|---|---|---|---|---|---|---|
| IC-8/12 (21) | IC-12/16 | IC-12/18 | ( | IC-12/18X | EM | Testost. | Androst. | ||
| Weight (g) | 128.3 ± 105.2 | 58.1 ± 26.2 | 68.6 ± 32.6 | 0.128 | 304.2 ± 169.2 | / | 0.626 * (65) | 0.387 * (64) | |
| Testes (cm) | wi | 4.4 ± 1.8 | 3.5 ± 0.9 | 3.8 ± 0.8 | 0.333 | 6.5 ± 2.0 | 5.0/7.5 | 0.550 * (67) | 0.379 * (66) |
| le | 6.5 ± 1.7 | 5.2 ± 0.86 | 5.8 ± 1.1 ~ | 0.210 | 10.3 ± 3.0 | 10.3/8.1 | 0.566 * (67) | 0.435 * (66) | |
| GlBu (cm) | wi | 2.1 ± 0.9a | 1.4 ± 0.6b | 1.6 ± 0.5ab | 0.039 | 2.8 ± 1.0 | 7.5/4.9 | 0.638 * (67) | 0.451 * (66) |
| le | 8.3 ± 2.5a | 6.4 ± 1.2b | 7.2 ± 1.3ab | 0.017 | 11.0 ± 3.5 | 12.2/8.9 | 0.584 * (68) | 0.478 * (67) | |
| GlVe (cm) | wi | 3.2 ± 2.0a | 1.7 ± 0.7b | 2.2 ± 0.9ab | 0.041 | 5.0 ± 2.8 | 5.0/3.1 | 0.561 * (68) | 0.442 * (67) |
| le | 4.9 ± 2.6 | 3.4 ± 0.9 | 3.8 ± 1.0 | 0.079 | 7.3 ± 3.1 | 11.3/7.9 | 0.554 * (68) | 0.396 * (67) | |
| GlPr (cm) | wi | 1.0 ± 0.8 | 0.7 ± 0.4 | 0.9 ± 0.4 | 0.213 | 2.2 ± 1.0 | 6.2/6.9 | 0.486 * (68) | 0.265 * (67) |
| le | 2.5 ± 0.8 | 2.2 ± 1.0 | 2.3 ± 0.7 | 0.440 | 4.0 ± 1.1 | 3.1/3.3 | 0.534 * (68) | 0.362 * (67) | |
Values with differing superscripts within a column differ significantly (p < 0.05) between groups; ~ n = 17; r: correlation coefficient (Spearman Rho); * significant correlation (p < 0.05); wi: width; le: length; GlBu: Glandula bulbourethralis; GlVe: Glandula vesicularis; GlPr: Glandula prostatica; Testost.: testosterone in serum; Androst.: Androstenone in fat tissue; entire males (EM); immunocastrated boars in 8th and 12th wk (week of live) (IC8/12); 12th and 16th wk (IC12/16); 12th and 18th wk (IC12/18), and long term follow-up group (IC-12/18X).